News | February 17, 2026
Indian pharma market grew 10.2% yoy in January 2026
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Subscribe To Our Newsletter & Stay Updated
